Karuna Therapeutics' top-experimental schizophrenia drug significantly reduced symptoms in a late-stage trial but there were concerns that it could cause hypertension in patients.
Share:
More In Science
Oatly Launches Climate Impact Labels
Oatly has launched climate footprint labels on its products in North America.
Amid 'Energy Trilemma,' BP Predicts Fossil Fuel Use Will Plummet by 2050
British energy giant BP predicts that fossil fuels as a primary energy source will decline from 80 percent in 2019 to between 55 and 20 percent in 2050.
Need2Know: January 31, 2023
First responders fired after video of police beating Tyre Nichols was released, 10 people show in Lanland, Fla. and winter storm is causing travel troubles. Here is everything you Need2Know for January 31, 2023.
How FluentPet Wants to Help Dog Owners Communicate With Their Pets
Los Angeles-based FluentPet has developed a series of tiles it claims help four-legged companions communicate with their humans.
WHO: COVID Still an Emergency but Nearing 'Inflection' Point
The World Health Organization chief says the coronavirus remains a global health emergency.
FDA Eases Rules for Blood Donations for Gay Men
The Food and Drug Administration is changing its policy to make it easier for gay men to donate blood.
The Future Of Space Is Female
Blue Origin is sending an all-female crew into orbit next year, according to The Wall Street Journal.
Jeff Bezos Girlfriend To Lead All Female Blue Origin Flight
Jeff Bezos' girlfriend is leading an all-female space mission aboard a Blue Origin spacecraft.
FDA Warns About Long-Term CBD Effects
The Food and Drug Administration is raising concerns about the long-term effects of CBD.
